Literature DB >> 29206314

Inhibition of spinal p38 MAPK prevents articular neutrophil infiltration in experimental arthritis via sympathetic activation.

Alexandre Kanashiro1,2, Marcelo Franchin3, Gabriel Shimizu Bassi4,5, Dênis Augusto Reis Santana2, Thiago Mattar Cunha2, Fernando Queiróz Cunha2, Luis Ulloa6, Gerson Jonathan Rodrigues1.   

Abstract

The central nervous system controls the innate immunity by modulating efferent neuronal networks. Recently, we have reported that central brain stimulation inhibits inflammatory responses. In the present study, we investigate whether spinal p38 mitogen-activated protein kinase (MAPK) affects joint inflammation in experimental arthritis. Firstly, we observed that intra-articular administration of zymosan in mice induces the phosphorylation of the spinal cord p38 MAPK. In addition, we demonstrated that spinal p38 MAPK inhibition with intrathecal injection of SB203580, a conventional and well-characterized inhibitor, prevents knee joint neutrophil recruitment, edema formation, experimental score and cytokine production. This local anti-inflammatory effect was completely abolished with chemical sympathectomy (guanethidine) and beta-adrenergic receptors blockade (nadolol). In conclusion, our results suggest that pharmacological strategies involving the modulation of spinal p38 MAPK circuit can prevent joint inflammation via sympathetic networks and beta-adrenoceptors activation.
© 2017 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Keywords:  arthritis; beta-adrenergic receptors; neuroimmunomodulation; neutrophil; p38 MAPK; sympathetic nervous system

Mesh:

Substances:

Year:  2017        PMID: 29206314      PMCID: PMC6262227          DOI: 10.1111/fcp.12338

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  34 in total

Review 1.  Current understanding of rheumatoid arthritis therapy.

Authors:  Inés Colmegna; Brent R Ohata; Henri A Menard
Journal:  Clin Pharmacol Ther       Date:  2012-02-22       Impact factor: 6.875

2.  The sympathetic nervous system stimulates anti-inflammatory B cells in collagen-type II-induced arthritis.

Authors:  Georg Pongratz; Madlen Melzer; Rainer H Straub
Journal:  Ann Rheum Dis       Date:  2011-09-27       Impact factor: 19.103

3.  Voluntary activation of the sympathetic nervous system and attenuation of the innate immune response in humans.

Authors:  Matthijs Kox; Lucas T van Eijk; Jelle Zwaag; Joanne van den Wildenberg; Fred C G J Sweep; Johannes G van der Hoeven; Peter Pickkers
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-05       Impact factor: 11.205

4.  Resident joint tissues, rather than infiltrating neutrophils and monocytes, are the predominant sources of TNF-alpha in zymosan-induced arthritis.

Authors:  E R Pettipher; E D Salter
Journal:  Cytokine       Date:  1996-02       Impact factor: 3.861

5.  Zymosan-induced arthritis: a model of chronic proliferative arthritis following activation of the alternative pathway of complement.

Authors:  E C Keystone; H U Schorlemmer; C Pope; A C Allison
Journal:  Arthritis Rheum       Date:  1977 Sep-Oct

6.  Interleukin-1beta and tumor necrosis factor-alpha produce distinct, time-dependent patterns of acute arthritis in the rat knee.

Authors:  B Bolon; G Campagnuolo; L Zhu; D Duryea; D Zack; U Feige
Journal:  Vet Pathol       Date:  2004-05       Impact factor: 2.221

Review 7.  Function of the sympathetic supply in acute and chronic experimental joint inflammation.

Authors:  Hans-Georg Schaible; Rainer H Straub
Journal:  Auton Neurosci       Date:  2013-12-24       Impact factor: 3.145

8.  Pharmacological Beta-Adrenergic Receptor Activation Attenuates Neutrophil Recruitment by a Mechanism Dependent on Nicotinic Receptor and the Spleen.

Authors:  Rangel L Silva; Fernanda V Castanheira; Jozi G Figueiredo; Gabriel S Bassi; Sérgio H Ferreira; Fernando Q Cunha; Thiago M Cunha; Alexandre Kanashiro
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

9.  Regulation of peripheral inflammation by spinal p38 MAP kinase in rats.

Authors:  David L Boyle; Toni L Jones; Deepa Hammaker; Camille I Svensson; Sanna Rosengren; Salvatore Albani; Linda Sorkin; Gary S Firestein
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

10.  Increased sympathetic nerve activity and reduced cardiac baroreflex sensitivity in rheumatoid arthritis.

Authors:  Ahmed M Adlan; Julian F R Paton; Gregory Y H Lip; George D Kitas; James P Fisher
Journal:  J Physiol       Date:  2016-10-24       Impact factor: 5.182

View more
  6 in total

1.  From neuroimunomodulation to bioelectronic treatment of rheumatoid arthritis.

Authors:  Alexandre Kanashiro; Gabriel Shimizu Bassi; Fernando de Queiróz Cunha; Luis Ulloa
Journal:  Bioelectron Med (Lond)       Date:  2018-05

2.  Lipoxin A4-Mediated p38 MAPK Signaling Pathway Protects Mice Against Collagen-Induced Arthritis.

Authors:  Jinyu Li; Qi Sun; Chenying Zheng; Chunxiao Bai; Chuyin Liu; Xueqian Zhao; Peiying Deng; Limin Chai; Yusong Jia
Journal:  Biochem Genet       Date:  2020-11-22       Impact factor: 1.890

Review 3.  Review of Perioperative Music Medicine: Mechanisms of Pain and Stress Reduction Around Surgery.

Authors:  J P Ginsberg; Karthik Raghunathan; Gabriel Bassi; Luis Ulloa
Journal:  Front Med (Lausanne)       Date:  2022-02-04

4.  Electroacupuncture at ST36 (Zusanli) Prevents T-Cell Lymphopenia and Improves Survival in Septic Mice.

Authors:  Zhi-Ying Lv; Yang-Lin Shi; Gabriel Shimizu Bassi; Yan-Jiao Chen; Lei-Miao Yin; Yu Wang; Luis Ulloa; Yong-Qing Yang; Yu-Dong Xu
Journal:  J Inflamm Res       Date:  2022-05-03

5.  Driving β2- While Suppressing α-Adrenergic Receptor Activity Suppresses Joint Pathology in Inflammatory Arthritis.

Authors:  Denise L Bellinger; Carlo Wood; Jon E Wergedal; Dianne Lorton
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

Review 6.  ASK1 inhibition: a therapeutic strategy with multi-system benefits.

Authors:  Jacqueline M Ogier; Bryony A Nayagam; Paul J Lockhart
Journal:  J Mol Med (Berl)       Date:  2020-02-14       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.